Unwanted side effect found with certain combination cancer treatment

December 04, 2001

Chemotherapy drug associated with lung inflammation in breast cancer patients

Treating cancer patients with radiation plus chemotherapy is often an effective strategy, but researchers at Massachusetts General Hospital (MGH) have found that certain combinations may increase the incidence of an inflammatory condition called radiation pneumonitis in breast cancer patients. Published in the December 5 Journal of the National Cancer Institute, the results suggest that doctors use extra caution when administering radiation therapy with the chemotherapy drug paclitaxel.

"The bottom line is that these treatments can cause this potentially serious form of lung inflammation, so we need to be alert and wary of it," says senior investigator Simon Powell, MD, PhD, a radiation oncologist at MGH.

Alphonse Taghian MD, PhD, lead author of the study, and his colleagues found that, when breast cancer patients were given chemotherapy that included paclitaxel in addition to radiation therapy directed at the breast-chest wall, radiation pneumonitis developed in six of the 41 patients, or 14.6 percent. For patients treated with chemotherapy drugs that did not include paclitaxel, the rate of lung inflammation was only 1.1 percent.

"There's some controversy over the effectiveness of paclitaxel in addition to standard chemotherapy," says Powell. "Now we're adding this additional information about using the drug in conjunction with radiation therapy." Taghian explains that radiation pneumonitis is an acute inflammation of the lung, and symptoms include shortness of breath, cough and low-grade fever. He stresses that the success rate of treatment for pneumonitis is almost 100 percent, though.

"This complication should not make the patient refuse paclitaxel. It can be delivered safely in combination with radiation, but we need to use extra caution in the placement of the radiation beams," says Taghian, also of the MGH radiation oncology department.

Doctors and patients who are not aware of this potential side effect will benefit from the new information. "This is a miniature alert on something doctors don't always look for," says Powell. "We had to look carefully to spot the occurrence of this condition; now we can alert others to do the same."
-end-
Other MGH researchers involved in this study include Sherif Assaad, MD, Andrzej Niemierko, PhD, Irene Kuter, MD, Jerry Younger, MD, Robin Schoenthaler, MD, and Maria Roche, MS, RNCS. Support for this study was provided in part by Public Health Service grants from the National Institutes of Health.

The Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $300 million and major research centers in AIDS, the neurosciences, cardiovascular research, cancer, cutaneous biology, transplantation biology and photomedicine. In 1994, the MGH joined with Brigham and Women's Hospital to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups and nonacute and home health services.

Massachusetts General Hospital

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.